A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study
- 1 June 2023
- journal article
- research article
- Published by Elsevier BV in European Urology
- Vol. 83 (6), 486-494
- https://doi.org/10.1016/j.eururo.2023.01.017
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non–Muscle-invasive Bladder CancerEuropean Urology, 2016
- Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive DiseaseBladder Cancer, 2016
- Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerBladder Cancer, 2016
- The role of PD-L1 in the radiation response and clinical outcome for bladder cancerScientific Reports, 2016
- Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCGBladder Cancer, 2015
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder CancerThe New England Journal of Medicine, 2012
- Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trialTrials, 2009
- PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomataCancer, 2007
- Novel designs for multi‐arm clinical trials with survival outcomes with an application in ovarian cancerStatistics in Medicine, 2003